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ABSTRACT: Speciﬁc folate receptors are abundantly overex-
pressed in chronically activated macrophages and in most cancer
cells. Directed folate receptor targeting using liposomes is
usually achieved using folate linked to a phospholipid or
cholesterol anchor. This link is formed using a large spacer like
polyethylene glycol. Here, we report an innovative strategy for
targeted liposome delivery that uses a hydrophobic fragment of
surfactant protein D linked to folate. Our proposed spacer is a
small 4 amino acid residue linker. The peptide conjugate inserts
deeply into the lipid bilayer without aﬀecting liposomal
integrity, with high stability and speciﬁcity. To compare the
drug delivery potential of both liposomal targeting systems, we
encapsulated the nuclear dye Hoechst 34580. The eventual
increase in blue ﬂuorescence would only be detectable upon liposome disruption, leading to speciﬁc binding of this dye to DNA.
Our delivery system was proven to be more eﬃcient (2-fold) in Caco-2 cells than classic systems where the folate moiety is
linked to liposomes by polyethylene glycol.
■ INTRODUCTION
Liposomes have gained extensive attention as carriers for a wide
range of drugs due to properties such as sustained release,
altered pharmacokinetics, increased drug stability, ability to
overcome drug resistance, and target speciﬁc tissues.1 Folate
receptor (FR), one of the most studied molecular targets for
directed therapy, is a glycoprotein with high aﬃnity for folate
(or folic acid, FA) (Kd ∼ 100 pM).
2,3 Two main membrane
variants of the FR exist, FRα and FRβ. FRα is overexpressed in
about 40% of human carcinomas. FRβ, by contrast, is expressed
in its functional form on activated macrophages and
myelogenous leukemia blasts.4 Both these FRs are absent in
most normal tissues. FR-targeting liposomes, with FA
covalently attached via a polyethylene glycol (PEG) linker to
a phospholipid or cholesterol (CH) anchor and incorporated
into the bilayer during liposome preparation, were previously
developed.5−8 Although these FA conjugates were shown to
successfully target FR-overexpressing cancer cells, self-aggrega-
tion of FA at the liposome surface has often been observed
when using such formulations, leading to reduced FR targeting
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eﬃciency.6 Furthermore, there are concerns over the two
negative charges carried by FA-PEG-phospholipid and the use
of a carbamate linker in FA-PEG-CH, which has limited
hydrolytic stability.9
Here, we report the design of a bifunctional peptide, derived
from the neck domain of pulmonary surfactant-associated
protein D (SP-D),10 that simultaneously serves as an FA linker
and as an anchor. Mammalian pulmonary surfactant proteins
can, in nature, promote the self-assembly of phospholipids
toward zero potential interface,11 suggesting that fragments or
models of these proteins are capable of recognizing and
interacting with liposomal phospholipids. These ﬁndings
prompted us to investigate the use of pulmonary surfactant
proteins for the preparation of targeted liposomes. The α-
helical neck region of SP-D shows an aﬃnity for phospholipids
and thus might promote the binding of SP-D to these
structures,12 further supporting their potential use as linker
and anchor for FA conjugates. We designed several subsets of
liposome formulations to show the funtionality of our ﬁnal
system containing the peptide SP-DS3. Their lipid membrane
insertion ability was extensively characterized, and tests were
performed to evaluate the potential of this formulation as a
speciﬁc drug delivery system.
■ EXPERIMENTAL SECTION
Materials. 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine
(DOPE) and N-(carbonyl methoxypolyethylene glycol-2000)-1,2-
distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-MPEG) were
obtained from Lipoid GmbH (Germany), and DSPE-PEG-FA was
obtained from Avanti Polar Lipids (USA). CH, ﬂuorescein
isothiocyanate (FITC), carbon monoxide-releasing molecule-2
(CORM-2) and methotrexate (MTX) were obtained from Sigma
(USA). Celecoxib was obtained from Cadila Pharmaceuticals, Ltd.
(India).
Peptide Synthesis. The neck-domain peptides constructed from
SP-D were synthesized by JPT Peptide Technologies GmbH (Berlin,
Germany) and American Peptide (Sunnyvale, CA, USA). FA was
covalently bound at the N-terminus of the peptides via glutamic acid
and pteroic acid, using a standard Fmoc-based solid-phase synthesis
protocol. Benzotriazole-1-yl-oxy-tris-pyrrolidino phosphoniumhexa-
ﬂuorophosphate was applied as the activating reagent to ensure
eﬃcient coupling. Fmoc protecting groups were removed after every
coupling step under standard conditions (20% piperidine in DMF).
Oregon Green 488 was covalently bound at the C-terminus. Peptides
were puriﬁed to greater than 75% homogeneity, as determined by
analytical high-performance liquid chromatography (Supporting
Information Figure S1), and characterized by mass spectrometry
(Figure S2).
Liposome Preparation. Liposomes composed of DOPE/CH/
DSPE-MPEG were prepared using a thin ﬁlm hydration method.
Brieﬂy, known amounts of DOPE, CH and DSPE-MPEG were
dissolved in chloroform in a 50 mL round-bottom ﬂask. In liposomes
with DSPE-PEG-FA, this compound was also added in this step. For
macrophage internalization studies, FITC was incorporated in the
lipidic ﬁlm, in the hydrocarbon region of the bilayer. The organic
solvent was evaporated using a rotary evaporator followed by
additional evaporation under reduced pressure by a high-vacuum
system to remove remaining traces of chloroform. The resultant dried
lipid ﬁlm was dispersed in phosphate-buﬀered saline (PBS) buﬀer
containing either peptides. The mixture was vortex-mixed at a
temperature greater than the phase-transition temperature (room
temperature) to yield multilamellar vesicles, which were then extruded
(extruder supplied by Lipex Biomembranes Inc., Vancouver, Canada)
through 200 nm pore size polycarbonate ﬁlters (Nucleopore) followed
by several passages through 100 nm polycarbonate ﬁlters (Nucleo-
pore) to form large unilamellar vesicles. The free peptide and drugs
that were not incorporated into liposomes were removed from the
samples after passage through a gel ﬁltration chromatography column
(GE Healthcare), with 5 kDa cutoﬀ (PD-10 Desalting Columns
containing 8.3 mL of Sephadex G-25 Medium).
Determination of the Zeta Potential and Size Distribution.
The zeta-potential (ζ-potential) values and size distribution of
liposomes were determined at pH 7.4 (PBS buﬀer) and 25.0 °C by
electrophoretic laser Doppler anemometry and photon correlation
spectroscopy (PCS), respectively, using a Malvern Zetasizer NS
(Malvern Instruments). The lipid concentration was held constant at
400 μM. The viscosity and refractive index values were 0.890 cP and
1.330, respectively.
Folic Acid Quantiﬁcation. The quantiﬁcation of FA present at the
liposomal surface was performed using a RIDASCREEN FAST Folic
Acid kit (R-Biopharm, Germany) according to the manufacturer’s
instructions. This kit is a competitive enzyme immunoassay and
quantiﬁes the folic acid at the liposomal surface.
Fluorescence Spectroscopy. Fluorescence experiments were
performed using a Fluorolog spectroﬂuorometer (JY Horiba) with a
1 × 1 cm quartz cell thermostated at 25.0 °C. The band-pass of the
excitation slit was set to 2.0 nm to obtain an optimal signal-to-noise
ratio without photodegradation. Fluorescence was excited at 280 nm,
and the emission was scanned from 310 to 450 nm at an increment of
1 nm and an integration time of 1 s.
Hydrophobic Photolabeling. The photoactivatable phosphati-
dylcholine analogue [125I]TID-PC/16 was prepared as described by
Mangialavori et al. (2009).13 A dried ﬁlm of the photoactivatable
reagent [125I]TID-PC/16 was suspended in 0.005% C12E10 and
liposomes incorporating SP-DS3. The samples were incubated for 20
min at room temperature in the dark before being irradiated for 20
min with light from a ﬁltered UV source (λ = 366 nm).
Radioactivity and Protein Determination. Electrophoresis was
performed according to the Tris-Tricine SDS-PAGE method. Peptide
was stained with Coomassie BlueR, the isolated bands were excised
from the gel, and the incorporation of radioactivity was directly
measured with a gamma counter. The amount of protein was
quantiﬁed by eluting each stained band, including bovine serum
albumin, in each gel for protein quantiﬁcation. Speciﬁc incorporation
was calculated as the ratio between the measured radioactivity and the
amount of protein determined for each band.
Molecular Dynamics Simulations. The simulations were
performed with the GROMACS 4.0.714 package using the Gromos
ﬀG43a1 force ﬁeld. The bond lengths were constrained using
LINCS.15 Nonbonded interactions were calculated using a twin-
range method with short- and long-range cut-oﬀs of 0.8 and 1.2 nm,
respectively. Neighbor searching was updated every ﬁve steps. An
integration time step of 2 fs was used. A reaction ﬁeld correction for
the electrostatic interactions was applied using a dielectric constant of
15. Pressure control was implemented using a Berendsen barostat16
with a reference pressure of 1 bar, a relaxation time of 0.5 ps and an
isothermal compressibility of 4.5 × 10−5 bar−1. Temperature control
was set at 300 K using a Berendsen thermostat.16 Each component of
the system was included in separate heat baths with temperature
coupling constants of 0.1 ps. Five replicate simulations were performed
using diﬀerent initial velocities determined from a Maxwell−
Boltzmann distribution at 300 K.
Electron Microscopy Imaging. For scanning transmission
electron microscopy (STEM) analysis, a liposomal suspension was
dropped onto carbon ﬁlm over copper grids (400 mesh, 3 mm
diameter). The shape and morphology of the liposomes were observed
using a NOVA Nano SEM 200 FEI system. For transmission electron
microscopy (TEM) analysis, the liposome samples were diluted 1:20
in distilled water and applied to glow-discharged carbon-coated copper
grids followed by negative staining with a solution of 1% (w/v) uranyl
acetate. Imaging was performed using a JEOL JEM2100F transmission
electron microscope operating at an acceleration voltage of 200 kV.
Images were recorded with a 4k*4k CCD camera (Tietz Video and
Image Processing Systems GmbH, Gauting, Germany) at a
magniﬁcation of 100 000×.
Cell Culture Conditions. The human colonic epithelial cell line
(Caco-2) (ATCC, HTB-37) was obtained from the American Type
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Culture Collection. Cells were maintained in Dulbecco's modiﬁed
Eagle medium (DMEM) containing 4 mM L-glutamine, 4.5 g/L
glucose, and 1.5 g/L sodium bicarbonate supplemented with 10% (v/
v) of fetal bovine serum (FBS), 1% (v/v) penicillin/streptomycin
solution, and 1% (v/v) nonessentials amino acids. The cells were
maintained at 37 °C in a humidiﬁed atmosphere of 5% CO2. Caco-2
cells were routinely subcultured over 7 days, and the culture medium
was replaced every 2 days. Caco-2 cells were plated at 106 cells/well in
six-well dishes for 10 days. Cells were stimulated by incubation with a
mixture of proinﬂammatory cytokines (Cytomix; 40 ng/mL each of
interferon-γ, interleukin-1β and tumor necrosis factor (TNFα) for 16
h.
Cell Viability Assay. Cells were seeded at a density of 10 × 103
cells per 100 μL per well on 96-well TCPS plates (TPP, Switzerland)
the day before the experiments and then exposed to diﬀerent liposome
and drug concentrations. At determined time of exposure, cell viability
was determined using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-
thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. A
ready-for-use CellTiter 96 Aqueous One solution of MTS (Promega,
Madison, WI) was used according to the protocol suggested by the
manufacturer. The culture medium was refreshed, and 20 μL of
CellTiter 96 Aqueous One solution was added to each well. After 4 h
of incubation at 37 °C, the absorbance at 490 nm was measured using
a microplate reader (Spectramax 340PC).
Cytometer Analysis. The determination of ﬂuorescence intensity
was assessed by ﬂow cytometer analysis, using FACScalibur from BD
Biosciences. Brieﬂy, cells were incubated for 1 h with 100 μg/mL
liposomes in complete medium at 37 °C. As a negative control,
macrophages were incubated just with complete medium. After
incubation, cells were washed twice with PBS (pH 7.4) and then
resuspended in PBS for ﬂuorescence-activated cell sorting (FACS)
analysis. The internalization was determined as the geometrical mean
ﬂuorescence intensity of liposomes corrected for the background
staining of cells incubated with no nanoparticles (negative control)
and normalized by the internalization level of each formulation.
Confocal Laser Scanning Microscopy (CLSM). Multilamellar
vesicles of liposomes incorporating SP-DS3 were used as a model to
perform CLSM experiments with a Leica TCS SPE confocal
microscope (Leica Microsystems GmbH, Mannheim, Germany).
Laser light wavelengths of 488 nm were used for the excitation of
Oregon Green 488. The emitted light was detected in the range of
500−556 nm. Every optical ﬁeld, laser intensity, photomultiplier gain
and oﬀset was individually adjusted to optimize the signal/noise ratio.
Confocal stacks were acquired with an ACS APO 63.0× 1.30 oil-
immersion objective lens while applying a Z-step of 6.01 μm. For
liposomal internalization studies, Caco-2 cells were seeded at a density
of 5 × 105 cells per 500 μL per well on 22 mm coverslips inserted into
the wells of 24-well tissue culture polystyrene (TCPS) plates (TPP,
Switzerland). After 10 days of adhesion, with the medium refreshed
every 2 days, the medium was removed, and cells were washed twice
with PBS. The cells were incubated with FR-targeted liposomes and
nontargeted control liposomes, labeled with FITC at a phospholipid
concentration of 100 μg/mL and diluted in Hank’s balanced salt
solution (HBSS) medium. After 1.5 h of exposure, the medium was
removed, and cells were washed three times with acid and basic PBS at
4 °C to remove receptor-bound free folate and not internalized
liposomes. The cells were then ﬁxed with 4% paraformaldehyde for 30
min. The cells were further washed three times with PBS. After drying,
the coverslips were put on slides coated with 2 μL of Vectashield
mounting medium (VECTOR) and sealed. Slides were examined
using an inverted Zeiss confocal laser scanning microscope (CLSM,
Olympus Fluoview FV1000). Volume rendering and 3D models were
created with the software Imaris7.0 (Bitplane, Zurich, Switzerland).
RNA Isolation, cDNA Synthesis and Quantitative Reverse
Transcription Polymerase Chain Reaction (RT-PCR). Total RNA
was extracted using the SV Total RNA Isolation System (Promega)
according to the manufacturer’s instructions and quantiﬁed with a
NanoDrop ND-1000 spectrophotometer (Nanodrop Technologies,
Wilmington, DE). Reverse transcription (RT) was performed using
the iScript cDNA synthesis kit (BioRad) with a unique blended
oligo(dT) and random hexamer primers, according to the
manufacturer’s protocols. Quantiﬁcation of gene expression was
performed with a CFX96 Real Time PCR Detection System from
BioRad using reagents and protocols from the TaqMan Gene
Expression Assay Protocol (Applied Biosystems). Each sample was
normalized against the expression of mitochondrially encoded ATP
synthase (MT-ATP6) as a stable internal control. The assay IDs of the
TaqMan Gene Expression Assays were Hs02596862_g1 (MT-ATP6),
Hs00153133_m1 (COX-2), HS00174103_m1 (IL-8), and
Hs01042796_m1 (MMP7).
Statistical Analysis. Statistical analyses were performed with
GraphPad Prism software (version 5.0). Unless otherwise stated,
Figure 1. SP-DS3 peptide, derived from pulmonary surfactant-associated protein D, is deeply inserted into the liposomal bilayer with FA at the
liposomal surface. (A) Diagram of the analyzed SP-D fragments. The localization in the SP-D sequence is indicated, and numbers correspond to the
amino acid positions in the SP-D sequence. (B) Description of the designed peptide linkers and quantiﬁcation of the FA present at the liposomal
surface. (C) Tryptophan ﬂuorescence of the tested peptides. A strong blue shift in the ﬂuorescence emission maximum was observed for SP-DS3.
(D) Molecular dynamics simulation of the interaction of SP-DS3 with the PC/CH membrane. The tryptophan residue (yellow) in an apolar
environment and the FA (orange) at the membrane surface. (E) Representative TEM images of liposomes. Scale bar (red) represents 200 nm in
smaller magniﬁcation and 20 nm in higher magniﬁcation.
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diﬀerences were tested for statistical signiﬁcance by a one-way
ANOVA.
■ RESULTS AND DISCUSSION
Interaction of Peptide with Liposomes. We started by
analyzing the interaction of three diﬀerent peptide sequences
(corresponding to amino acids 235−248 of SP-D; Figure 1A)
with a liposomal formulation composed of DOPE/CH/DSPE-
MPEG. At the N-terminus of the peptide, a hydrophilic
bifunctional peptide spacer (DRDD) previously described in
the literature, was added to improve the aqueous solubility of
the ﬁnal FA conjugate under physiological conditions.17,18 The
quantiﬁcation of FA at the liposomal surface (Figure 1B)
demonstrated the utility using of this hydrophilic spacer as
liposomes with a peptide linker lacking the spacer DRDD (SP-
D3) did not show quantiﬁable FA at the surface in contrast to
liposomes with peptide linkers SP-DS1 and SP-DS3.
Furthermore, SP-DS2 presence led to a reduced FA
concentration at the surface and thus was excluded in
subsequent studies. Tryptophan ﬂuorescence and a photo-
activatable phosphatidylcholine analogue were used to
discriminate between deep insertion of the peptide in the
bilayer and poor adsorption at the membrane surface. A
tryptophan residue was included at position 5 from the C-
terminus of the peptide sequence. A blue shift in the
wavelength of maximum ﬂuorescence emission is known to
occur when tryptophan is transferred from a polar medium to a
less polar environment. The results demonstrated that both
peptide linkers penetrate into the liposomes; however, a
pronounced blue shift was observed in the liposomal
formulation using SP-DS3 (330 nm vs 342 nm for SP-DS1),
suggesting that this peptide penetrates deeper into the non
polar hydrocarbon region of the bilayer than does SP-DS1
(Figure 1C). A deep insertion of SP-DS3 prevents their
dissociation from the liposome after intravenous injection.
Therefore, this peptide was selected for further the studies.
To conﬁrm the deep insertion of SP-DS3 in the bilayer, we
used the photoactivatable phosphatidylcholine analogue
[125I]TID PC/16, which has been used to identify and
characterize regions within membrane proteins that interact
with lipids.19 [125I]TID PC/16 positions itself in the
phospholipid milieu and, upon photolysis, reacts with the
peptide if present in the vicinity.20,21 During the reaction
between the photoactivatable group and the peptide, the aryl
group is transferred to the peptide and quantiﬁed via 125I,
demonstrating that SP-DS3 was incorporated in the phospho-
lipid milieu. To further assess the behavior of SP-DS3 in the
lipid bilayer, a molecular modeling study was performed using
GROMACS software. The resultant model indicated that FA is
located at the membrane surface, whereas SP-DS3 is deeply
inserted into the lipid bilayer with the tryptophan residue in
contact with the hydrocarbon region (Figure 1D). This model
is consistent with the experimental results described above.
CLSM analysis revealed the homogeneous distribution of SP-
DS3 (with Oregon Green 488 dye covalently bound at the C-
terminus) in contact with hydrophilic regions both on the
liposomal surface of multilamellar vesicles (MLV) and in the
aqueous core (data not shown). Using STEM (data not shown)
and TEM (Figure 1E) imaging, we showed that nanocapsules
of liposomes integrating SP-DS3 have a spherical form with a
uniform diameter of approximately 120 nm. This size
distribution was conﬁrmed by dynamic light scattering (DLS)
measurements (Table S1). Both liposomal formulations
exhibited a narrow size distribution (polydispersity index
<0.1), indicating that all liposome preparations had similar
physicochemical characteristics. After 16 weeks of storage in
PBS (pH 7.4) at 4 °C, the particle sizes of either formulations
remained unaltered, suggesting a high stability of these
liposomes in terms of size distribution. Furthermore, ζ-
potential values remained unchanged (close to zero) during
this time. To evaluate the cytotoxicity of the liposomal
formulations, an important parameter for biological applica-
tions, cell viability, was assessed by several assays using
immortalized cell lines. Liposomal formulations did not induce
toxicity over a wide range of concentrations (up to 750 μg/mL
and 72 h; Figure S3). Furthermore, liposomal formulations did
not induce hemolysis in rat blood (Figure S4).
Figure 2. Liposomes with FA conjugated to SP-DS3 peptide are more eﬃciently disrupted compared to DSPE-PEG-FA. (A) Schematic
representation of liposomes incorporating SP-DS3 peptide and (B) DSPE-PEG-FA. Representative pictures of the Caco-2 cells (FR+) after 1 h of
incubation with ﬂuorescent liposomal formulations (Hoechst 34580, blue staining) (C) with SP-DS3 and (D) DSPE-PEG-FA. (E) Eﬃcient
membrane disruption of liposomes incorporating SP-DS3 peptide, comparing with DSPE-PEG-FA, by Caco-2 cells. Graphs represent the relative
mean ﬂuorescence intensity (MFI) determined by ﬂow cytometry analysis of Hoechst 34580 in Caco-2 cells with internalized liposomes after 1 h of
incubation at 37 °C. Values are the mean + SD of 2 experiments. (F) Structures of DSPE-PEG-FA and SP-DS3.
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To evaluate the eﬃciency of FA targeting in liposomes
integrating SP-DS3, we used a human colorectal carcinoma
derived cell line (Caco-2) overexpressing FRα.22,23 Caco-2 cells
have also been used not only as an in vitro cancer model but
also as a model of chronic inﬂammation.24 The images obtained
by CLSM showed that FR-targeting liposomes labeled with
FITC are well internalized by FR-expressing Caco-2 cells in
comparison with nontargeted control liposomes (Figure S5). In
our recent study,25 we measured the uptake of these FR-
targeting liposomes in the monocytic cell line THP-1 with and
without overexpression of human FRβ. Liposomes with FA
were highly internalized by THP-1 cells retrovirally transformed
with FRβ in comparison with the wild-type THP-1 cells, which
weakly express FRβ, that showed minimal uptake.25 Further-
more, the in vivo uptake speciﬁcity of these new liposomes in a
pathological context of rheumatoid arthritis, was also measured.
In comparison to liposomes without FA, SP-DS3 liposomes
strongly accumulated in the joints of arthritic mice.25
Furthermore, in vivo evaluation of the clinical beneﬁt of
liposomal formulations encapsulating the anti-inﬂammatory
drug MTX, indicated that SP-DS3 liposomes loaded with MTX
improved prophylactic eﬃcacy and thus the mice did not show
any clinical signs of the disease.25
Evaluation of the FA-Tailed Peptide Eﬃciency. The
eﬃciency of liposomal membrane disruption was compared
between the optimized liposomal formulation containing SP-
DS3 peptide (Figure 2A) or DSPE-PEG-FA (Figure 2B), a
commonly used FA conjugate.26 In the present study,
encapsulated Hoechst 34580 was used to evaluate the eﬃciency
of liposomal membrane disruption, through detection of an
eventual increase in blue ﬂuorescence derived from to the
speciﬁc binding of this dye to DNA. The results clearly indicate
that liposomes with FA conjugated to SP-DS3 peptide are more
eﬃciently disrupted in Caco-2 cells, and consequently may
quickly deliver the vectorized compounds (Figures 2C,D and
S6). Approximately 2-fold more Hoechst-associated ﬂuores-
cence was detected by ﬂow cytometer analysis with targeted
liposomes incorporating SP-DS3, relatively to those prepared
with DSPE-MPEG (Figure 2E). We propose that the
mechanism of liposomal membrane disruption is more eﬃcient
due to the smaller size of the hydrophilic bifunctional peptide
spacer (DRDD), as compared to PEG (Figure 2F). This
implies that the close contact between liposome and cell can
lead to major liposomal membrane deformation in the process
of receptor binding and internalization, and consequently faster
and more eﬀective disruption.
Evaluation of Liposomes Incorporating FA-Tailed
Peptide as a Drug Delivery System. We further tested
the capacity of SP-DS3 liposomes to encapsulate and
speciﬁcally deliver drugs into targeted cells. Liposomes loaded
with one of two hydrophobic anti-inﬂammatory drugs,
celecoxib and CORM-2, or a hydrophilic antiarthritic and
antineoplastic FA analogue, MTX, were produced.27,28
Physicochemical characterization was performed, and the
respective data, similar to that obtained for unloaded liposomes
(Table S1), indicate that drugs are encapsulated inside the
liposomes. The concentration of encapsulated drug was
determined for each liposomal formulation, and the biological
eﬀect was compared with that of the same concentration of free
drug. Celecoxib is a selective inhibitor of cyclooxygenase-2
(COX-2) and exerts its eﬀects by inhibiting the synthesis of
prostaglandins involved in pain, fever, and inﬂammation.29,30
Previous reports show that celecoxib strongly decreases protein
expression of COX-2, which is directly proportional to a
decrease of mRNA levels.31−33 Since (q) PCR is a very sensitive
technique, it was considered the best option to monitor this
highly regulated pathway. We observed that celecoxib-loaded
liposomes decreased the expression of COX-2 (Figure 3A),
which is consistent with the ﬂuorescence data showing that
these liposomes can be internalized to some extent by Caco-2
cells. This reduction was much more pronounced in liposomes
integrating SP-DS3, which showed similar levels to those
obtained with celecoxib alone, indicating the eﬀective release of
the cargo from the targeted liposomes in vitro.
Similar results were obtained with SP-DS3 liposomes
encapsulating CORM-234 assessed in Caco-2 cells stimulated
with pro-inﬂammatory cytokines (Cytomix); mRNA levels of
interleukin-8 (IL-8) and metalloproteinase-7 (MMP-7), which
are crucial for cancer cell proliferation and invasion, were
quantiﬁed.24 A previous publication showed that CORM-2
simultaneously decreases both protein and mRNA levels of IL-8
and MMP-7.24 Both mRNAs were strongly diminished
compared with those from cells incubated with liposomes or
CORM-2 alone (Figure S7). Of note was the eﬀect of unloaded
SP-DS3 liposomes in the expression of these inﬂammatory
mediators as well as of COX-2. Indeed, the presence of FA,
Figure 3. Liposomes integrating SP-DS3 are an eﬃcient drug delivery system to FR-expressing cells. (A) The eﬀects of 250 μg/mL of liposomal
formulations with and without 65 μM celecoxib on COX-2 mRNA expression in Caco-2 cells (3 h of contact with liposomes +21 h of medium
without liposomes). Values are the mean + SD of 2 experiments. (B) Caco-2 cell viability after 3, 6, and 48 h of contact with 10 μg/mL liposomal
formulations encapsulating 1.27 μM methotrexate compared with untreated cells (negative control) and 30% DMSO-treated cells (positive control)
as determined by the MTS assay at 48 h. Values are the mean + SD of 2 experiments. Signiﬁcant diﬀerences were detected as shown by an asterisk (P
< 0.05) and two asterisks (P < 0.005).
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vitamin B9, is associated with an attenuation of inﬂammation
and reduction in pro-inﬂammatory cytokine levels.35 SP-DS3
liposomes were also tested for the eﬃcient delivery of MTX.
Liposomes encapsulating MTX signiﬁcantly reduced the
viability of Caco-2 cells (Figure 3B), whereas empty liposomes
had no eﬀect. This cytotoxic eﬀect was enhanced in cells
contacting SP-DS3 liposomes, suggesting preferential internal-
ization of these targeted liposomes. Collectively, these data
demonstrate that our delivery system is eﬃcient in the
encapsulation and speciﬁc delivery of both hydrophobic and
hydrophilic drugs.
■ CONCLUSION
In conclusion, we have successfully developed novel FR-
targeted liposomes by incorporating a bifunctional SP-DS3
peptide consisting of the neck domain present in surfactant
proteins, which serves as both a linker and an anchor of the FA
to the liposomal membrane. This peptide, linked to a speciﬁc
hydrophilic peptide spacer, was shown to insert deeply into the
lipid bilayer without aﬀecting the integrity of the liposomes.
Furthermore, our delivery system was proved to be more
eﬃcient than classic systems where the FA is linked to
liposomes by PEG. The combination of all complementary
characteristics of these tailored liposomes, including their small
size, lack of cytotoxicity and their speciﬁc targeting of FR-
expressing cells, supports their use as speciﬁc therapeutic
nanodelivery systems as demonstrated here by the biological
eﬀect of several drugs. The use of liposomes equipped with the
novel bifunctional SP-DS3 peptide linker reported here for FA-
mediated delivery opens new opportunities for the treatment of
human diseases, including chronic inﬂammatory diseases and
cancer.
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